IOVANCE BIOTHERAPEUTICS, INC. - COMMON STOCK (IOVA) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2017 to Q4 2025

Type / Class
Equity / COMMON STOCK
Symbol
IOVA on Nasdaq
Shares outstanding
395,322,451
Price per share
$2.63
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
261,295,244
Total reported value
$713,224,486
% of total 13F portfolios
0%
Share change
+48,182,565
Value change
+$133,485,487
Number of holders
256
Price from insider filings
$2.63
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of IOVANCE BIOTHERAPEUTICS, INC. - COMMON STOCK (IOVA) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
VANGUARD GROUP INC 7.5% $43,131,532 25,076,472 The Vanguard Group 30 Jun 2025
BlackRock, Inc. 6.4% $36,645,720 21,305,651 BlackRock, Inc. 30 Jun 2025
STATE STREET CORP 5.1% $55,847,203 20,161,445 STATE STREET CORPORATION 31 Dec 2025
PERCEPTIVE ADVISORS LLC 3.8% -50% $45,599,285 -$33,120,382 12,808,788 -42% Perceptive Advisors LLC 31 Mar 2025

As of 31 Dec 2025, 256 institutional investors reported holding 261,295,244 shares of IOVANCE BIOTHERAPEUTICS, INC. - COMMON STOCK (IOVA). This represents 66% of the company’s total 395,322,451 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of IOVANCE BIOTHERAPEUTICS, INC. - COMMON STOCK (IOVA) together control 56% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 7.5% 29,518,125 +14% 0% $80,584,481
MHR FUND MANAGEMENT LLC 7.3% 28,967,103 0% 6.8% $79,080,191
VANGUARD GROUP INC 6.9% 27,207,079 +13% 0% $74,275,326
STATE STREET CORP 5.1% 20,161,445 +51% 0% $55,040,745
BANK OF AMERICA CORP /DE/ 3.6% 14,277,813 +127% 0% $38,978,430
Invenomic Capital Management LP 3% 11,959,505 +13% 1.6% $32,649,449
MORGAN STANLEY 2.3% 9,191,840 +65% 0% $25,093,723
GOLDMAN SACHS GROUP INC 2.2% 8,607,564 +31% 0% $23,498,650
Long Focus Capital Management, LLC 2.2% 8,600,000 -5.7% 1.2% $23,478,000
GEODE CAPITAL MANAGEMENT, LLC 2% 7,991,640 +16% 0% $21,820,558
Palo Alto Investors LP 1.8% 7,116,676 -6.6% 2.7% $19,428,525
MILLENNIUM MANAGEMENT LLC 1.7% 6,585,532 +49% 0.01% $17,978,502
SUSQUEHANNA INTERNATIONAL GROUP, LLP 1.3% 4,948,614 +50% 0.02% $13,509,716
TWO SIGMA INVESTMENTS, LP 1.1% 4,397,989 +60% 0.02% $12,006,510
HRT FINANCIAL LP 1.1% 4,356,010 +1078% 0.04% $11,891,000
D. E. Shaw & Co., Inc. 0.97% 3,829,795 +4925% 0.01% $10,455,340
JANE STREET GROUP, LLC 0.91% 3,583,810 +154% 0.01% $9,783,801
CITADEL ADVISORS LLC 0.8% 3,143,091 -18% 0.01% $8,580,638
TWO SIGMA ADVISERS, LP 0.76% 3,015,000 +185% 0.02% $8,230,950
JPMORGAN CHASE & CO 0.76% 3,001,502 +145% 0% $8,194,101
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.7% 2,753,343 +9.9% 0% $7,516,626
NORTHERN TRUST CORP 0.65% 2,579,594 +4.8% 0% $7,042,291
WELLS FARGO & COMPANY/MN 0.5% 1,993,337 +31% 0% $5,441,810
Orion Investment Co 0.47% 1,856,934 +0.28% 1.6% $5,069,430
Rhenman & Partners Asset Management AB 0.4% 1,595,327 +45% 0.41% $4,355,243

Institutional Holders of IOVANCE BIOTHERAPEUTICS, INC. - COMMON STOCK (IOVA) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 261,295,244 $713,224,486 +$133,485,487 $2.73 256
2025 Q3 213,023,331 $462,262,436 -$12,426,305 $2.17 249
2025 Q2 220,039,758 $378,480,610 -$103,966,458 $1.72 244
2025 Q1 239,455,648 $797,796,916 -$41,501,290 $3.33 292
2024 Q4 241,507,506 $1,786,983,312 +$22,988,107 $7.40 294
2024 Q3 235,201,336 $2,210,596,727 +$25,452,589 $9.39 280
2024 Q2 232,474,427 $1,864,558,933 +$97,335,567 $8.02 287
2024 Q1 217,101,064 $3,216,301,753 +$212,421,390 $14.82 266
2023 Q4 207,297,037 $1,685,397,432 -$32,505,370 $8.13 233
2023 Q3 213,137,480 $969,776,344 +$6,686,675 $4.55 223
2023 Q2 203,959,385 $1,435,734,710 -$789,310 $7.04 214
2023 Q1 205,425,383 $1,254,751,936 +$199,378,894 $6.11 225
2022 Q4 173,249,347 $1,106,975,435 +$100,178,837 $6.39 213
2022 Q3 154,414,415 $1,478,691,442 -$53,630,372 $9.58 231
2022 Q2 156,417,705 $1,726,071,008 +$13,073,879 $11.04 227
2022 Q1 155,843,237 $2,593,671,140 -$16,926,612 $16.65 231
2021 Q4 155,850,778 $2,963,320,040 -$77,138,233 $19.09 235
2021 Q3 157,966,360 $3,882,977,675 -$126,474,780 $24.66 238
2021 Q2 162,111,422 $4,215,394,735 +$75,696,267 $26.02 226
2021 Q1 156,513,608 $4,954,837,773 +$228,194,179 $31.66 240
2020 Q4 148,752,147 $6,902,468,525 +$436,980,892 $46.40 264
2020 Q3 139,955,271 $4,606,819,956 -$20,115,200 $32.92 245
2020 Q2 140,811,545 $3,876,458,222 +$501,586,010 $27.45 254
2020 Q1 122,545,305 $3,667,866,974 -$30,050,711 $29.94 214
2019 Q4 124,152,367 $3,436,416,158 +$2,487,658 $27.68 196
2019 Q3 123,451,560 $2,246,787,056 +$1,725,871 $18.20 169
2019 Q2 122,286,530 $2,995,401,566 +$230,321,379 $24.52 162
2019 Q1 117,236,707 $1,114,459,029 -$10,984,795 $9.51 147
2018 Q4 118,553,949 $1,048,865,157 +$237,101,241 $8.85 134
2018 Q3 90,396,956 $1,016,473,349 +$78,564,266 $11.25 129
2018 Q2 83,236,651 $1,065,503,232 +$54,089,415 $12.80 124
2018 Q1 77,770,935 $1,312,527,807 +$341,021,805 $16.90 120
2017 Q4 57,639,452 $460,738,120 +$14,620,712 $8.00 85
2017 Q3 55,295,141 $428,707,093 +$59,837,958 $7.75 85
2017 Q2 47,622,569 $349,319,767 +$349,310,767 $7.35 82